In addition, GLP-1RA is known to lower the risk of cardiovascular disease, and it may also prevent the onset of AD caused by cerebrovascular disorders
Therefore, the use of several sub-strains of mice is a strength of this study [49, 50], and suggests that our findings are more likely to generalize to other mouse sub-strains than they would have if the study were conducted in only one strain of mice
is an employee of Gubra Aps, which conducted the trial
Notably, 31% of patients on GLP-1 RAs became completely headache-free at 6 months, versus only 8% of those on usual care (this difference did not remain significant after adjusting for weight loss)
Two very different populations, however the approach to helping both groups is actually very similar